Therefore, various biopharmaceutical engineering approaches may be adopted to develop IGFBP2 analogues and mimetics with improved physiological properties in obesity and insulin sensitivity, pharmacokinetic profiles and potency that are suitable for future clinical development. This evidence concerns the gene IGFBP2 and obesity due to melanocortin 4 receptor deficiency.